Clinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study - Scorecard - MDSpire
Advertisement
Clinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study
Clinical Scorecard: Outcomes in Cancer Patients with Prior Autoimmune Thyroid Disorders Undergoing Treatment with PD-(L)-1 Inhibitors: A Retrospective Study Utilizing Propensity Score Analysis and Inverse Probability Weighting
At a Glance
Category
Detail
Condition
Thyroid dysfunction as an immune-related adverse event in cancer patients treated with PD-(L)-1 inhibitors
Key Mechanisms
Target Population
Care Setting
Key Highlights
OS
Guideline-Based Recommendations
Diagnosis
Management
Monitor for thyroid irAEs in patients with pre-existing thyroid autoantibodies
Implement specific follow-up actions for patients developing thyroid irAEs.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
585 patients with malignancy treated with PD-(L)-1 inhibitors
Preexisting thyroid antibodies are a significant risk factor for thyroid irAEs
Clinical Best Practices
Utilize propensity score matching and inverse probability weighting to minimize confounding biases
Conduct comprehensive reviews of medical records for accurate assessment of endocrine irAEs
Encourage interdisciplinary collaboration in managing thyroid irAEs.
